Antonio Manuel
Lax Perez
Investigador "Ramon y Cajal"
Publications (55) Publications de Antonio Manuel Lax Perez
2023
-
Circulating ST2, from biomarker to pathogenic mediator
Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 672-674
-
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
Molecular Therapy - Nucleic Acids, Vol. 32, pp. 704-720
2022
-
Critical warm ischemia time point for cardiac donation after circulatory death
American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328
-
Editorial: Myocardial Remodeling: Mechanisms and Translational Implications
Frontiers in Pharmacology
2021
-
The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
Scientific Reports, Vol. 11, Núm. 1
2020
-
Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status (Scientific Reports, (2020), 10, 1, (13553), 10.1038/s41598-020-70454-8)
Scientific Reports
-
Differences in the Interleukin-1β/Soluble ST2 Interplay Between Acute and Chronic Heart Failure
Journal of Cardiovascular Translational Research
-
Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
Scientific Reports, Vol. 10, Núm. 1
2019
-
Reply: Interleukin-1β and sST2
Journal of the American College of Cardiology
-
Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction
Diabetes and Metabolism
-
The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure
Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1016-1025
-
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
JACC: Basic to Translational Science, Vol. 4, Núm. 7, pp. 831-840
-
Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction
Journal of Molecular and Cellular Cardiology, Vol. 130, pp. 216-233
2018
-
Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)
American Journal of Cardiology, Vol. 122, Núm. 4, pp. 578-583
-
Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology
-
Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction
Translational Research, Vol. 199, pp. 4-23
-
Pulmonary Production of Soluble ST2 in Heart Failure
Circulation. Heart failure, Vol. 11, Núm. 12, pp. e005488
2017
-
Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes
PLoS ONE, Vol. 12, Núm. 2
-
Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction
Journal of Cardiovascular Translational Research, Vol. 10, Núm. 5-6, pp. 460-469
2016
-
Atrial fibrillation management in older heart failure patients: A complex clinical problem
Heart International, Vol. 11, Núm. 1, pp. e41-e49